Herbert Loong, Advisor at Greater Bay Area International Clinical Trial Institute, and Steering Committee Member at Lung Cancer Policy Network, shared a post on LinkedIn:
“My thanks to OncoDaily for organising and choosing sarcomas as the topic for the first OncoDaily Grand Rounds on the sidelines of ASCO26 in Chicago this year.
Happy to share my lecture on Antibody Drug Conjugates as a new treatment modality in sarcomas.”
How Close Are We to a Cure? ADCs in Sarcoma Treatment | Dr. Herbert Loong
Dr. Loong provides a comprehensive overview of ADC technology, explaining how these targeted therapies work, the importance of antibody selection, linker design, payload delivery, and the impact of ADCs on the tumor microenvironment. He discusses why ADCs are becoming one of the most exciting areas of oncology drug development and how they are helping move sarcoma treatment toward a more precise and personalized approach.
The presentation highlights key clinical developments, including promising data from B7-H3-targeted ADCs such as HS20093, results from the ARTEMIS-2 clinical trial in osteosarcoma and soft tissue sarcoma, and emerging evidence supporting new therapeutic targets like AXL. Dr. Loong also reviews innovative strategies designed to improve therapeutic efficacy and reduce toxicity, including conditionally activated biologics (CABs) and next-generation ADC platforms.
You can also read:
OncoDaily Grand Rounds at ASCO 2026: Sarcoma Edition Brought Global Experts Together in Chicago
